Jeito Capital

Portfolio Co Investors 2026 for Jeito Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Jeito Capital accounts for 18 tracked companies with verified cap-table data, 18 of which disclose round sizes totalling $3.4B. The median disclosed raise is $130M, and the largest is Odyssey Therapeutics at $726M, ahead of Alentis Therapeutics ($366M) and Quell Therapeutics ($344M).

The names that recur most often on these co-invested cap tables are Jeito Capital (18 companies), Omega Funds (6 companies), Novo Holdings (5 companies), OrbiMed (3 companies), SV Health Investors (3 companies), Forbion (3 companies). By latest disclosed round, the market skews Series A (7), Series B (6), Series D (4), Series C (1).

Best funded Jeito Capital companies

  1. Odyssey Therapeutics — $726M (latest: Series D)
  2. Alentis Therapeutics — $366M (latest: Series D)
  3. Quell Therapeutics — $344M (latest: Series B)
  4. Catalym — $319M (latest: Series D)
  5. Alveus Therapeutics — $197M (latest: Series A)
  6. Callio Therapeutics — $187M (latest: Series A)
  7. Noema Pharma — $171M (latest: Series B)
  8. SparingVision — $147M (latest: Series B)
  9. Eyebiotech — $130M (latest: Series A)
  10. Precirix — $124M (latest: Series B)
  11. Pulmocide — $122M (latest: Series C)
  12. XyloCor Therapeutics — $108M (latest: Series B)
  13. Augustine Therapeutics — $104M (latest: Series A)
  14. CDR-Life AG — $90M (latest: Series A)
  15. NMD Pharma — $79M (latest: Series B)

Jeito Capital — related firms and companies (56)

Jeito Capital alternatives · All research reports